Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

Table 3

Association between single-nucleotide polymorphisms and changes in visual acuity score and central retinal thickness.

SNP	VA score change					CRT change (𝜇m)
	Letters			≥15 letters gain		𝑁	Median	𝑃^∗
	𝑁	Mean ± SD	𝑃	𝑛 (%)	𝑃
CFH rs800292
TT	11	17.6±17.6	0.065	7 (63.6)	0.041	11	−120.0	0.620
TC	56	10.0±14.0		19 (33.9)		53	−47.0
CC	73	7.3±13.1		19 (26.0)		65	−71.0
ARMS2 rs10490924
GG	16	12.4±10.9	0.005	6 (37.5)	0.015	16	−134.0	0.445
GT	44	14.0±13.5		21 (47.7)		38	−69.0
TT	83	6.0±13.9		19 (22.9)		77	−81.0
HTRA1 rs11200638
GG	16	12.4±10.9	0.002	6 (37.5)	0.027	16	−134.0	0.473
GA	43	14.5±12.7		20 (46.5)		37	−71.0
AA	85	5.9±14.1		20 (23.5)		79	−81.0

CRT: central retinal thickness; SD: standard deviation; SNP: single-nucleotide polymorphism; VA: visual acuity.
*Nonparametric testing.